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Delirium is a common and debilitating syndrome in hospitalised patients, and its impact 
on mortality, morbidity and duration of hospital admission is increasingly apparent. 
Delirium is a complex phenomenon, for which there is no specific treatment, but 
research over the last decade has revealed contributing factors, many of which are 
modifiable, and preventative strategies have demonstrated benefit.  This review 
highlights the importance of reducing the impact of delirium on hospitalised patients, 
and summarises the current evidence for strategies to achieve this.  Current 
recommendations focus on the pre-emptive implementation of multi-modal non-
pharmacological interventions to reduce the occurrence of delirium in the first place, 
and routine monitoring using validated tools to identify delirious patients early.  




 Delirium is associated with a higher mortality, morbidity and longer stays in 
hospital, with negative impact on quality of life long after discharge.  
 
 Delirium is grossly underdiagnosed, and must be screened for daily in hospital 
patients 
 
 Multicomponent, non-pharmacological interventions have proven effective in 
decreasing the occurrence of delirium. 
 
 Evidence for the benefit of pharmacological approaches to delirium prevention 




Delirium is a common affliction, its presence detected in approximately one fifth of 
general hospital inpatients 1, and its incidence increasing to 30% in the elderly 2 and 
80% of  the critically unwell 3. Perhaps because of its ubiquity, it is easy to dismiss as 
merely an unavoidable consequence of illness, but delirium is independently associated 
with increased mortality, as well as longer stays in hospital, and on the intensive care 
unit 4.  Each additional day of delirium is associated with an average of 10 extra days 
in hospital and a 10% increased risk of death, with an association of long-term cognitive 
impairment 5. MRI has shown an association between the duration of delirium and 
cerebral atrophy and white matter disruption 6.  
Various theories have been proposed to describe the pathophysiology underlying 
delirium, including cerebral inflammation altering the blood-brain-barrier and changes 
in neurotransmitter levels, such as reduced cholinergic activity or increased 
catecholamine serotonergic activity 7.  More recently, it has been proposed that the 
features of delirium may be a clinical manifestation of circadian rhythm disruption 8. 
Both illness and the hospital environment itself disrupt the usual 24 hour cycles that 
govern human behaviour (such as sleeping, waking, eating and physical activity), 
physiological indices (temperature, heart rate, urine output) and intracellular processes 
(gene expression, enzyme activity and mitochondrial function) 9.  The circadian 
oscillation in these diverse functions is synchronised to the time of day, through the 
light-dark cycle and other cues such as regular feeding times.  One of the early signs of 
delirium is inversion of the sleep-wake cycle, and this has led to the hypothesis that 
delirium may represent the observable signs of underlying circadian dysrthythmia, the 
impact of which extends much deeper, affecting a multitude of cellular and organ 
system functions. Prevention, identification and treatment of delirium are key priorities 
for improving clinical outcomes for all patients admitted to hospital.  Here we review 
the current evidence for strategies to reduce the impact of delirium on hospital patients. 
 
Diagnosing delirium 
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) 
delirium is a disturbance in attention (reduced ability to focus, sustain and shift 
attention), awareness and cognition over a short period of time (hours to a few days) 
and fluctuates in severity during the course of the day 10. Delirium can manifest in three 
different ways: hyperactive (agitated), hypoactive (withdrawn) and mixed (alternating 
periods of hyperactive and hypoactive). The most common type is mixed followed by 
hypoactive delirium11. The form of delirium most likely to go unrecognised is 
hypoactive delirium, and it is associated with the worst prognosis 12.  The presence of 
delirium is consistently underdiagnosed, with detection rates by clinical staff as shown 
to be as low as 25% 13.  Diagnosis requires regular and repeated screening as, without 
it, the majority of delirium cases go unnoticed 1 The National Institute of Health and 
Care Excellence (NICE) recommends that all patients are observed at least daily for 
recent changes or fluctuations of usual behaviour, and if present, a formal assessment 
must be carried out to confirm the diagnosis.  All patients in an intensive care unit 
should be formally assessed for delirium at least once every 12 hours using a validated 
screening tool14.  The Confusion Assessment Method (CAM) is the most widely used 
in clinical practice 15, and has been adapted for the Intensive Care Unit (CAM-ICU) 14.  
Other screening tools were recently reviewed, including the Delirium Rating Scale 
(found to be most useful for psychiatric and geriatric patients), and the Nurses’ 
Delirium Screening Checklist (best for recovery room setting) 15. 
 
Primary prevention of delirium  
The most effective strategy for reducing the impact of delirium is to prevent its 
occurrence in the first place.  Delirium is precipitated by multiple factors, all of which 
must be addressed.  Risk factors for delirium are divided into four domains 16.  The first 
two: patient characteristics (such as age, alcohol use, smoking) and chronic pathology 
(such as pre-existing cognitive impairment) are important for identifying those most at 
risk, for prioritisation in any delirium prevention strategy. The latter two, acute illness 
and the environment, may be amenable to modification and offer a target for reducing 
delirium and improving clinical outcomes.  Multicomponent strategies which minimise 
these risk factors have consistently demonstrated efficacy in reducing delirium 
incidence.  A recent systematic review and meta-analysis including 14 interventional 
studies concluded that multi-modal non-pharmacological interventions can be effective 
in preventing delirium and falls during a hospital admission in the elderly, with 11 
studies showing decreases in delirium incidence (odds ratio 0.47, 95% CI 0.42-0.76), 
and rate of falls reduced by 64% in two randomised or matched trials 17.  These bundles 
typically include measures to ensure adequate oxygenation, hydration, nutrition and 
analgesia.  They prompt staff to facilitate mobilisation, as well as provide necessary 
aides for vision and hearing.  Modifications to the environment may help in reducing 
circadian disruption, by promoting daytime cues such as adequately bright light to 
simulate the light intensity of outdoors and supporting physical activity and social 
interaction in the day.  Relatives should be actively encouraged to visit and bring cues 
such as photographs and familiar music.  Patients should be reminded verbally of the 
time, date and location. Provision of easily visible clocks and calendars aid in active 
reorientation.  At night, reducing sleep interference by minimising bright light, loud 
noises and avoidable clinical interventions, will promote sleep.  In a cohort study in a 
mixed ICU, the implementation of a bundle of environmental interventions to promote 
sleep led to an increase in qualitative as well as quantitative measures of sleep, which 
in turn led to a reduction in the incidence and duration of delirium from 33% to 14% 
18.  The bundle consisted of reducing the monitor alarms, telephone ringtones, 
providing eye masks, dimming the lights during nighttime, minimising non-clinical 
discussions around patients’ bed spaces, orientating the patients to time and place and 
date, documenting regular CAM-ICU assessments, addressing pain, assessing patients 
for sedation hold and setting sedation targets.  Figure 1 summarises the key components 
of an evidence-based delirium prevention strategy. 
 
As yet, there is insufficient evidence of benefit from any prophylactic pharmacological 
strategies. Only two trials have demonstrated reductions in postoperative delirium 
incidence with prophylactic administration of antipsychotics, such as intravenous 
haloperidol (0.5 mg bolus followed by 0.1mg/hr infusion for 12 hours) 19, and oral 
risperidone (0.5 mg twice daily) 20 but trials have been inconsistent.  Administration of 
the exogenous form of the circadian hormone melatonin (0.5 mg once nightly), was 
associated with a lower delirium incidence (12%) in elderly medical patients compared 
to placebo (31%) 21 but again, results from other studies have been conflicting 22. 
 
Treatment options for established delirium 
Despite the success of non-pharmacological strategies for the prevention of delirium, 
very few studies have assessed their efficacy in the treatment of established delirium.  
The first priority is to identify and treat any modifiable organic causes such as pain, 
hypoxia, acidaemia and other metabolic derangements, infection and haemodynamic 
instability 22.  Other organic causes, non-clinical seizures, hypertensive encephalopathy 
and intracerebral haemorrhage, should be ruled out on the basis of history, examination 
and investigation when appropriate.  It is important to review all drug side effects and 
drug interactions, or the impact of withdrawal of drugs, particularly in the context of 
pre-existing alcohol/substance abuse.  The following classes of drugs have been 
implicated in contributing to delirium: opioids, antidepressants, anticonvulsants, 
antihistamines, anstipsychotics, antimuscarinics and steroids. Less familiar, include 
assorted agents such as furosemide, ranitidine, atenolol and digoxin 14.  Although often 
a necessary evil in the ICU, sedative medications and deeper levels of sedation are 
associated with increased risk of delirium, with benzodiazepines appearing to be the 
worst culprits 23.    
 
Pharmacological approaches to treating delirium remain controversial. Antipsychotics 
are most commonly used in patients with hyperactive delirium where there is a risk to 
safety, but the side effects of the proposed drugs must be balanced against any benefit 
they may provide.  In delirium due to alcohol or benzodiazepine withdrawal, 
benzodiazepines offer a specific treatment, but otherwise it is advised to avoid these 
drugs as they can contribute to development of delirium.  Although antipsychotics, such 
as haloperidol, are included in guidelines as potential therapy for established delirium, 
a recent systematic review of the use of antipsychotics (including haloperidol, 
risperidone and olanzapine) for the treatment of delirium in elderly patients 
demonstrated no improvement in delirium duration, severity, mortality or hospital 
length of stay, in the 19 identified studies 24. In one randomised controlled trial of 247 
patients in the palliative care setting, those taking haloperidol or risperidone had greater 
delirium scores compared to those receiving placebo, and mortality rates were higher 
in those receiving haloperidol 25.  In the intensive care setting, dexmedetomidine, a 
selective alpha2-adrenoceptor agonist with analgesic and sedative effects, has shown 
promise in the treatment of hyperactive delirium.  In a randomised controlled trial of 
74 mechanically ventilated patients, those receiving dexmedetomidine had a shorter 
duration of delirium and increased number of ventilator-free hours at day 7, compared 
to those receiving placebo 26.  It is possible that this effect was due to the decrease in 
the amount of other sedative agents (propofol, opioids and midazolam) required by the 
treatment group compared to placebo.  This finding has been corroborated by the 
significantly lower prevalence of delirium in mechanically ventilated patients receiving 
dexmedetomidine for sedation rather than midazolam (54% compared to 77%) in a 
multicentre international prospective trial of 375 patients27.  Patients in the 
dexmedetomidine group also had more delirium-free days, and were extubated sooner 
than the midazolam group. 
 
Conclusions  
Illness and admission to hospital place a patient at risk of developing delirium, which 
has stark consequences for the individual, reducing their likelihood of survival, and 
dimishing their quality of life long after hospital discharge.  Once established, delirium 
is difficult to treat, but there is convincing evidence from clinical trials for the 
effectiveness of comprehensive bundles of care in preventing its onset in the first place.  
Detection and prevention of delirium should be a key priority for all healthcare 
professionals.  We recommend auditing delirium incidence, on the wards and in the 
intensive care unit, and for multidisciplinary clinical teams to take shared responsibility 




Figure 1. Components of a multi-faceted delirium prevention strategy. 
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